Quantifying the Lifetime Economic Impact of Pediatric Oral Nutritional Supplements

That is the title of a new paper published this week in Clinical Nutrition with co-authors Kyi-Sin Than, Khounish Sharma, Kirk W. Kerr, and Dhanasekhar Kesavelu. The abstract is below: IntroductionPediatric malnutrition is a significant global public health challenge, particularly in low- and middle-income countries. This study quantifies the lifetime, per-person economic impact of pediatric…

Read More

Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines

Gilead Sciences exercised its option license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership with C4 Therapeutics is focused on developing degrader antibody drug conjugates for undisclosed cancer targets. The post Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines appeared first on MedCity…

Read More